14-Aminocamptothecins: Their synthesis, preclinical activity, and potential use for cancer treatment

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1715-1723

  Duan, Jian Xin ^a   Cai, Xiaohong ^a   Meng, Fanying ^a   Sun, Jessica D ^a   Liu, Qian ^a   Jung, Donald ^a   Jiao, Hailong ^a   Matteucci, Jackson ^a   Jung, Brian ^a   Bhupathi, Deepthi ^a   Ahluwalia, Dharmendra ^a   Huang, Heli ^a   Hart, Charles P ^a   Matteucci, Mark ^a  

^a Threshold Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 AMINOCAMPTOTHECIN; 14 NITROCAMPTOTHECIN; 7 ETHYL 14 AMINOCAMPTOTHECIN; 7 ETHYL 14 NITROCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER THERAPY; CELL STRAIN HT29; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SOLID TUMOR; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW CELLS; BRAIN; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; SPECIES SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 79952783035     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101354u     Document Type: Article

References (30)

1. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata J. Am. Chem. Soc. 1966, 88, 3888-3890
2. Wang, J. C. DNA topoisomerases Annu. Rev. Biochem. 1996, 65, 635-692 (Pubitemid 26250622)
3. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K.; Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity J. Med. Chem. 1991, 34, 98-107
4. Negoro, S.; Fukuoka, M.; Masuda, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Niitani, H.; Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer J. Natl. Cancer Inst. 1991, 83, 1164-1168
5. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 1991, 51, 4187-4191
6. Basili, S.; Moro, S. Novel camptothecin derivatives as topoisomerase I inhibitors Expert Opin. Ther. Pat. 2009, 19, 555-574
7. Zunino, F.; Dallavalle, S.; Laccabue, D.; Beretta, G.; Merlini, L.; Piatesi, G. Current status and perspectives in the development of camptothecins Curr. Pharm. Des. 2002, 8, 2505-2520 (Pubitemid 35331535)
8. Sawada, S.; Matsuoka, S.; Nokata, K.; Nagata, H.; Furata, T.; Yokokura, T.; Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins Chem. Pharm. Bull. 1991, 12, 3183-3188
9. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues J. Med. Chem. 1986, 29, 2358-2363 (Pubitemid 17182317)
10. Cao, Z. Preparation of 14-nitrocamptothecin derivatives by reactions of camptothecin with nitronium tetrafluoroborate in acidic solvents J. Chem. Soc., Perkin Trans. 1 1996, 21, 2629-2632 (Pubitemid 126803664)
11. Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S.-M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J. Med. Chem. 1989, 32, 715-720 (Pubitemid 19075732)
12. Giovanella, B. C.; Hinz, H. R.; Kozielski, A. J.; Stehlin, J. S., Jr.; Silber, R; Potmesil, M. Complete growth inhibition of human cancer xanografts in nude mice by treatment with 20-(S)-camptothecin Cancer Res. 1991, 51, 3052-3055
13. Burke, T. G.; Munshi, C. B.; Mi, Z.; Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs J. Pharm. Sci. 1995, 84, 518-519
14. Loos, W. J.; Verweij, J.; Gelderblom, H. J.; DeJonge, M. J.; Brouwer, E.; Dallaire, B. K.; Sparreboom, A. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans Anticancer Drugs 1999, 10, 705-710 (Pubitemid 30015671)
15. Mi, Z.; Malak, H.; Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood Biochemistry 1995, 34, 13722-13728
16. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance Cancer Chemother. Pharmacol. 1997, 40 (Suppl) S3-S8
17. Ayrton, A.; Morgan, P. Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 2001, 31, 469-497 (Pubitemid 32826389)
18. Harker, W. G.; Sikic, B. I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA Cancer Res. 1985, 45, 4091-4096 (Pubitemid 16224856)
19. Hipfner, D. R.; Gauldie, S. D.; Deeley, R. G.; Cole, S; C., P. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies Cancer Res. 1994, 54, 5788-5792
20. Robey, R. W.; Honjo, Y.; Morisaki, K. Mutations at aminoacid 482 in the ABCG2 gene aVect substrate and antagonist specificity Br. J. Cancer 2003, 89, 1971-1978 (Pubitemid 37533279)
21. Kruijtzer, C. M. F.; Beijnen, J. H.; Schellens, J. H. M. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract andliver: an overview The Oncologist 2002, 7, 516-530 (Pubitemid 36009000)
22. Erickson-Miller, C. L.; May, R. D.; Tomaszewski, J.; Osborn, B.; Murphy, M. J.; Page, J. G.; Parchment, R. E. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro Cancer Chemother. Pharmacol. 1997, 39, 467-472 (Pubitemid 27078134)
23. Kirichenko, A. V.; Rich, T. A.; Newman, R. A.; Travis, E. L. Potentiation of murine MCa-4 carcinoma radio response by 9-amino-20-(S)-camptothecin Cancer Res. 1997, 57, 1929-1933 (Pubitemid 27209723)
24. Lamond, J. P.; Mehta, M. P.; Boothman, D. A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation J. Neurol.-Oncol. 1996, 30, 1-6 (Pubitemid 26265764)
25. Masubuchi, N.; May, R. D.; Atsumi, R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay Clin. Cancer Res. 2004, 10, 6722-6731 (Pubitemid 39346570)
26. Kurtzberg, L. S.; Battle, T.; Rouleau, C.; Bagley, R. G.; Agata, N.; Yao, M.; Schmid, S.; Roth, S.; Crawford, J.; Krumbholz, R.; Ewesuedo, R.; Yu, X. J.; Wang, F.; Lavoie, E. J.; Teicher, B. A. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors Mol Cancer Ther. 2008, 7, 3212-3222
27. Avgeropoulos, G. N.; Batchelor, T. T. New treatment strategies for malignant gliomas Oncologist 1999, 4, 209-224 (Pubitemid 29297484)
28. Feun, L.; Savaraj, N. Topoisomerase I inhibitors for the treatment of brain tumors Expert Rev. Anticancer Ther. 2008, 8 (5) 707-716
29. Li, T.-K.; Houghton, J. P.; Desai, D. S.; Daroui, P.; Liu, A. A.; Hars, S. E.; Ruchelman, L. A.; LaVoie, J. E.; Liu, F. L. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug Cancer Res. 2003, 63, 8400-8407 (Pubitemid 37549495)
30. Meng, F.; Ngnyen, X.-T.; Cai, X.; Duan, J.; Matteucci, M.; Hart, C. P. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1- accumulation Anti-Cancer Drugs 2007, 18 (4) 435-445 (Pubitemid 46712407)